CollectionsEndo Pharmaceuticals
IN THE NEWS

Endo Pharmaceuticals

FEATURED ARTICLES
BUSINESS
January 18, 2012 | By David Sell, Inquirer Staff Writer
If anybody was unsure about the appeal of boring-but-important infrastructure to business, Endo Pharmaceuticals chief executive officer Dave Holveck made it clear at Tuesday afternoon's groundbreaking for the company's new headquarters in Malvern, Chester County. "The turnpike exit was absolutely critical," Holveck said during an interview after the speeches, including that of Gov. Corbett. Within walking distance, a new interchange will connect the Pennsylvania Turnpike to Route 29 and will be the first in the state to be all electronic, with on- and off-ramps in each direction.
BUSINESS
September 18, 2014 | By David Sell, Inquirer Staff Writer
In a Philadelphia-area pharmaceutical takeover attempt, Endo International P.L.C. Tuesday offered to buy all of the shares of Auxilium Pharmaceuticals for $2.2 billion. After the New York Stock Exchange closed, Endo said in a statement that it "delivered a proposal to acquire all of the outstanding shares of Auxilium," for $28.10 per share in a cash and stock transaction that Endo valued at $2.2 billion. There was no immediate comment from Auxilium, whose stock closed Tuesday at $21.52.
BUSINESS
January 16, 2001 | By Susan Warner, INQUIRER STAFF WRITER
Endo Pharmaceuticals Inc., the Chadds Ford manufacturer of the painkiller Percocet, has sued a California generic-drug maker, alleging it stole trade secrets during failed negotiations over a possible business alliance. Endo said in a lawsuit filed Friday that Watson Pharmaceuticals Inc., of Corona, Calif., stole proprietary marketing and manufacturing information in the fall of 1998 after a presentation on Endo's primary business strategy to create a new variant of Percocet that includes acetaminophen, the generic name for Tylenol.
BUSINESS
December 21, 2012 | By David Sell, Inquirer Staff Writer
Perhaps only in the strange business of pharmaceuticals would a company sue to have a federal agency declare that one of its products was unsafe and then be disappointed when it lost the suit. But that's what happened with Endo Pharmaceuticals Inc., a subsidiary of Endo Health Solutions Inc., of Chadds Ford. The drug in question is Opana ER, first approved by the U.S. Food and Drug Administration in 2006. It is an opioid painkiller, a group of medicines that are controversial because of deadly overdoses by abusers.
BUSINESS
September 13, 1999 | By Leslie J. Nicholson, INQUIRER STAFF WRITER
In 1997, three executives of DuPont Merck Pharmaceutical Co. - now DuPont Pharmaceuticals - bought the company's Endo line of products and went into business for themselves. With the formation of Endo Pharmaceuticals Inc., they gained a business whose name goes back to the 1920s. They also gained a line of 62 products, including the familiar painkillers Percodan and Percocet. What they failed to gain was a computer system to run the whole thing. Months after the buyout, they still had to use DuPont's staff, and DuPont's in-house software, to handle orders, bidding, shipping and other customer-service functions, and to handle finance.
BUSINESS
February 9, 1998 | By David Wallace, FOR THE INQUIRER
One trip down a drugstore or supermarket aisle and you know that pain is big business. Pills, capsules, powders, gelcaps, heating pads, ice packs, rubs, ointments and liquids in a rainbow of colors all promise relief from pain. Drugstore remedies, though, are powerless against the often excruciating chronic pain of such diseases as AIDS and cancer, or the acute but severe pain that can follow surgery. Salving this kind of pain requires powerful, potentially addictive, prescription drugs.
NEWS
January 16, 2005 | By Melissa Dribben INQUIRER STAFF WRITER
The spring of her senior year, Carol Ammon and a few friends from New Hyde Park High School sneaked onto the roof of a terminal at John F. Kennedy International Airport. They were hanging out, watching planes land, when they heard someone coming. Her friends ducked under a turnstile to escape. Ammon took a running start and hurdled over it. She fell, breaking two fingers and loosening every tooth in her head. She needed her two front teeth replaced, her mouth wired, and her fingers splinted.
NEWS
September 19, 2011
Qualitest Pharmaceuticals, which was recently acquired by Endo Pharmaceuticals of Chadds Ford, is recalling multiple lots of birth-control pills because of a packaging error that could lead to incorrect dosing and unintended pregnancies. The company said the error caused the weekly tablet orientation within some packages to be reversed and obscured the lot number and expiration date. The problem could lead to inadequate contraception if women don't get the proper daily regimen of the drug.
NEWS
November 14, 2011
Endo Pharmaceuticals of Chadds Ford said in a filing with the Securities and Exchange Commission that it decided to stop development of its octreotide implant for the treatment of acromegaly. Caused by an excess of growth hormone, acromegaly's symptoms include abnormal enlargement in bones, especially in the jaw and front of the skull. The filing said the decision was based on the chances of success with that drug vs. the other products in the company pipeline and making best use of resources.
NEWS
April 14, 2011
I am a huge fan of The Inquirer, especially the investigative reporting of the last few years, but I have to say that you blew it on Tuesday. The big news that day was that a homegrown, cutting-edge success story, Endo Pharmaceuticals Inc., announced that it had reached a megadeal to acquire a Minnesota-based company, American Medical Systems, for $2.9 billion. This is one of several major acquisitions by Endo in the last two years. So, does The Inquirer lead its front page with this growth story?
1 | 2 | 3 | 4 | 5 | Next »
ARTICLES BY DATE
BUSINESS
March 17, 2015
Children's Village , a Philadelphia nonprofit that provides early-childhood education and school-age academic enrichment, has named Mark K. Stephens secretary of its board of directors. Stephens is a retired engineer with the Environmental Protection Agency. Also named to the board were Teri Gerbec , senior vice president, creative director, Tierney; Diana Lumia , attorney adviser, Social Security Administration; and Stephen T. Molieri , vice president, enterprise financial risk, Bancorp.
BUSINESS
September 18, 2014 | By David Sell, Inquirer Staff Writer
In a Philadelphia-area pharmaceutical takeover attempt, Endo International P.L.C. Tuesday offered to buy all of the shares of Auxilium Pharmaceuticals for $2.2 billion. After the New York Stock Exchange closed, Endo said in a statement that it "delivered a proposal to acquire all of the outstanding shares of Auxilium," for $28.10 per share in a cash and stock transaction that Endo valued at $2.2 billion. There was no immediate comment from Auxilium, whose stock closed Tuesday at $21.52.
BUSINESS
February 27, 2013 | By David Sell, Inquirer Staff Writer
Endo Health Solutions Inc., now has a new chief executive officer to go along with a new headquarters in Malvern, as the board of directors announced Monday that Rajiv De Silva will lead the drug and device company. Investors hope the stock price, revenue, and profits will also take a new direction - higher, of course - when the former Novartis and Valeant Pharmaceuticals executive takes over on March 18. Dave Holveck announced late last year that he would retire. De Silva, 46, will make $975,000 in salary and more through incentives and stock options, but he did not land this job because he mixed molecules in a lab. He earned degrees in civil engineering at Princeton and Stanford before getting his MBA at Wharton.
BUSINESS
December 21, 2012 | By David Sell, Inquirer Staff Writer
Perhaps only in the strange business of pharmaceuticals would a company sue to have a federal agency declare that one of its products was unsafe and then be disappointed when it lost the suit. But that's what happened with Endo Pharmaceuticals Inc., a subsidiary of Endo Health Solutions Inc., of Chadds Ford. The drug in question is Opana ER, first approved by the U.S. Food and Drug Administration in 2006. It is an opioid painkiller, a group of medicines that are controversial because of deadly overdoses by abusers.
BUSINESS
November 27, 2012
Securities trades recently reported to the Securities and Exchange Commission by officers, directors, and principal shareholders of corporations based or having sizable employment in the Philadelphia area. Titles are as reported to the SEC. Air Products & Chemicals Inc. Michael J Donahue , director, exercised an option for 2,000 shares at $41.96 on Nov. 19; the holdings were not reported. Ursula O. Fairbairn , director, sold 2,000 shares at $79.89 on Nov. 16, and now directly holds 1,135 shares.
BUSINESS
February 25, 2012 | By David Sell, Inquirer Staff Writer
Endo Pharmaceuticals, based in Chadds Ford, reported a 57 percent increase in revenue for the fourth quarter of 2011, but acquisition costs sliced profits by 61 percent. Revenue for the quarter rose to $803 million, compared with $511.2 million in the same quarter of 2010. Net income dropped from $93 million in the fourth quarter of 2010 to $36.6 million in the latest period. In June, Endo paid $2.9 billion for American Medical Systems, which helped with fourth-quarter revenue, but Endo repaid $140 million in debt on the purchase during the fourth quarter and $290 million for the year, which cut into profits.
BUSINESS
January 18, 2012 | By David Sell, Inquirer Staff Writer
If anybody was unsure about the appeal of boring-but-important infrastructure to business, Endo Pharmaceuticals chief executive officer Dave Holveck made it clear at Tuesday afternoon's groundbreaking for the company's new headquarters in Malvern, Chester County. "The turnpike exit was absolutely critical," Holveck said during an interview after the speeches, including that of Gov. Corbett. Within walking distance, a new interchange will connect the Pennsylvania Turnpike to Route 29 and will be the first in the state to be all electronic, with on- and off-ramps in each direction.
NEWS
November 14, 2011
Endo Pharmaceuticals of Chadds Ford said in a filing with the Securities and Exchange Commission that it decided to stop development of its octreotide implant for the treatment of acromegaly. Caused by an excess of growth hormone, acromegaly's symptoms include abnormal enlargement in bones, especially in the jaw and front of the skull. The filing said the decision was based on the chances of success with that drug vs. the other products in the company pipeline and making best use of resources.
BUSINESS
September 20, 2011
In the Region American Water hikes profit forecast American Water Works Co. Inc., Voorhees, raised its 2011 earnings guidance to a range of $1.75 to $1.82 per share from the previous range of $1.65 to $1.75 per share. The nationwide utility company said the change was due mainly to a rise in sales during the hot and dry July in the company's East Coast systems, favorable weather in the Midwest, cost efficiencies, and the continued expectations of a low-interest-rate environment.
NEWS
September 19, 2011
Qualitest Pharmaceuticals, which was recently acquired by Endo Pharmaceuticals of Chadds Ford, is recalling multiple lots of birth-control pills because of a packaging error that could lead to incorrect dosing and unintended pregnancies. The company said the error caused the weekly tablet orientation within some packages to be reversed and obscured the lot number and expiration date. The problem could lead to inadequate contraception if women don't get the proper daily regimen of the drug.
1 | 2 | Next »
|
|
|
|
|